Rogier Buijsman is Chief Executive Officer of Crossfire Oncology. He has more than 25 years of drug discovery experience. In 1998 he obtained his Ph.D. from the University of Leiden and started his career at Organon in the medicinal chemistry department where he initiated many successful kinase research programs. In 2011 he co-founded NTRC, a biotech company dedicated towards kinase inhibitor research. In 2021 he started Crossfire Oncology, as a spin-out of NTRC, a company dedicated towards degrader antibody conjugates or DACs in short.